LUNG Company Profile and Key Details

Q: Who are the executives of LUNG?

Mr. David A. LehmanGen. Counsel & Sec.Ms. Lisa PaulChief People OfficerMr. Sri RadhakrishnanChief Technical OfficerMr. Geoffrey Beran RoseChief Commercial OfficerMs. Marcee M. MaroneyVice President of MarketingMr. Jérôme ErathSenior Vice President & GM of Europe Middle-East & AfricaSarah HuberVice President of Sales (U.S.)Dr. Derrick Sung Ph.D.Chief Financial OfficerMs. Lauren CristinaVice President of Fin. & Admin. (U.S.)Mr. Glendon E. FrenchChief Executive Officer, Pres & Director

NASDAQ : LUNG

Pulmonx

$1.42

-0.03-2.07%

At Close 4:00 PM

56.79

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pulmonx Corporation (LUNG) stock declined over -2.07%, trading at $1.42 on NASDAQ, down from the previous close of $1.45. The stock opened at $1.46, fluctuating between $1.39 and $1.46 in the recent session.

Stock Snapshot

1.45

Prev. Close

58.57M

Market Cap

1.39

Day Low

-1.01

P/E Ratio

-1.41

EPS (TTM)

-1

Cash Flow per Share

1.46

Open

41.25M

Number of Shares

1.46

Day High

97.34%

Free Float in %

3.08

Book Value

285.47K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 12, 2026	1.46	1.46	1.39	1.42	285.81K
Feb 11, 2026	1.48	1.48	1.38	1.45	382.3K
Feb 10, 2026	1.54	1.56	1.45	1.45	347.42K
Feb 09, 2026	1.49	1.55	1.44	1.54	318.4K
Feb 06, 2026	1.48	1.51	1.45	1.50	348.67K
Feb 05, 2026	1.46	1.49	1.45	1.45	364.62K
Feb 04, 2026	1.58	1.62	1.45	1.50	529.76K
Feb 03, 2026	1.63	1.68	1.51	1.55	618.42K
Feb 02, 2026	1.62	1.73	1.62	1.63	427.52K
Jan 30, 2026	1.72	1.74	1.63	1.64	386.25K
Jan 29, 2026	1.77	1.77	1.68	1.72	172.3K
Jan 28, 2026	1.75	1.80	1.73	1.76	247.79K
Jan 27, 2026	1.77	1.80	1.74	1.75	233.66K
Jan 26, 2026	1.85	1.92	1.78	1.79	232.38K
Jan 23, 2026	1.91	1.91	1.85	1.85	152.19K
Jan 22, 2026	1.87	1.96	1.86	1.91	267.4K
Jan 21, 2026	1.78	1.87	1.77	1.86	233.63K
Jan 20, 2026	1.69	1.83	1.68	1.77	545.4K
Jan 16, 2026	1.99	1.99	1.76	1.77	285.44K
Jan 15, 2026	2.00	2.01	1.82	1.83	451.32K

Contact Details

Redwood City, CA 94063

United States

https://pulmonx.com 650 364 0400

About Company

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Stock Peers

SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 BRKRP

-34.21-10.45%

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$293.04 UFPT

-16.12-6.12%

UFP Technologies, Inc.$247.32 PODD

-10.03-4.00%

Insulet Corporation$240.82 ALGN

-13.65-6.91%

Align Technology, Inc.$183.86 IRTC

-3.7-2.43%

iRhythm Technologies, Inc.$148.41 TMDX

-4.78-3.59%

TransMedics Group, Inc.$128.52 IRMD

-3.24-3.14%

IRadimed Corporation$99.84 NARI

Inari Medical, Inc.$79.97 ESTA

0.82+1.13%

Establishment Labs Holdings Inc.$73.54

Company Overview

Pulmonx Corporation (NASDAQ:LUNG) closed at $1.42 USD, losing -$0.03 (-2.07%) from the previous close of $1.45. The stock is currently mid-range between its 52-week high and low $1.31 and $9.37. With a market capitalization of about $58.57 million, Pulmonx Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.07). Key stats such as the average daily volume over the past year has been around 668.43 thousand shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Pulmonx Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Glendon E. French, the company employs approximately 291 people and listed since October 01, 2020. Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -14.3%, SMA50 -29.33%, SMA200 -36.34%). The stock’s 14-day RSI is 29.22 (weak momentum), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.85% below its high and over 8.4% above its low. Average 10-day trading volume of 402.55 thousand shares is below the 3-month average of 701.83 thousand, indicating normal recent market interest.

Valuation Metrics

Pulmonx Corporation trades at a P/E ratio of -1.04, slightly below the S&P 500 average, with a price-to-sales ratio of 0.65 and a price-to-book ratio of 0.98 suggesting the stock is closer to book value. The P/FCF stands at -1.81, also above market averages.

Dividend & Fair Value

Pulmonx Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.07. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Pulmonx Corporation generated EPS of -$1.41 over the past year. Five-year average earnings growth is -19.8%. Wall Street analysts project EPS growth of 14.12% annually over the next five years. The latest quarter delivered EPS of -$0.34. The next quarter is forecast at -$0.39. Next year's EPS is expected at $3.52. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 10 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $2.50. The high target offers 1097.18% upside. The low target suggests 76.06% downside. The mean target is $10.43. This offers 634.51% upside. Pulmonx Corporation earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -15.0%. The prior quarter beat by -5.0%. Over the last six quarters, Apple has recorded several small beats. These include -4.88% in July 31, 2024.

Shareholding & Insider Activity

Pulmonx Corporation has 40.75 million shares outstanding. The public float is 39.69 million shares, elevated short interest at 4.92% of float. This equals 1.37 million shares. The short ratio is 2.28 days. Institutional investors hold 98.33% of the float. Insiders own 4.98%. Sung Derrick holds 391.04 thousand shares, Rose Geoffrey Beran has 373.47 thousand shares and Williamson Steven S. has 358.97 thousand shares. Over the past six months, insider transactions show net selling. They sold 49.27 thousand shares across 8 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Pulmonx generated $68.68M in revenue, or $1.81 per share. Gross margin was 73.32%, operating margin -90.19%, and net profit margin -88.60%. Returns are negative, with ROA at -34.00% and ROE at -51.42%.
On valuation metrics, Pulmonx trades at a P/E of -1.04, P/S of 0.65 and P/B of 0.98. The current ratio is 4.86 and quick ratio is 4.15. Operationally, the company’s inventory turnover is 1.51 and cash conversion cycle is 203.49 days. Debt-to-equity is 0.94, supported by a cash flow-to-debt ratio of -0.57.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pulmonx posted revenue of $68.68M, down slightly from $53.66M in the prior quarter. Gross profit was $50.35M (margin 73.32%). Operating income was - $61.94M (margin -90.2%). Net income was- $60.84M (EPS - $1.60).
The company ended the quarter with $117.34M in cash and short-term investments, a total debt of $41.42M, and net debt of - $42.36M. Total assets were $178.95M, with equity of $118.32M. Financials further reflected weakness, with operating cash flow of - $37.61M, free cash flow of - $38.42M, and capital expenditures of - $807.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Pulmonx Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.61%, with price expected at $1.17 by February 25, 2026, within a range of $1.09 to $1.26 3-Month Outlook: Projected fall of -52.82%, reaching $0.67 by May 12, 2026, with a range of $0.51 to $0.83. 1-Year Outlook: Projected loss of -9.86%, with price at $1.28 by February 11, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Pulmonx Corporation (NASDAQ:LUNG) shares are down -19.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pulmonx Corporation trading at a premium to the broader market with a P/E of -1.04. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.09, suggesting 1173.94% upside. Our AI forecast model points to short-term weakness (-17.61% over two weeks), a medium-term fall (-52.82% over three months), and a longer-term loss (-9.86% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Pulmonx Corporation (LUNG) stock price?

Pulmonx Corporation (NASDAQ: LUNG) stock price is $1.42 in the last trading session. During the trading session, LUNG stock reached the peak price of $1.46 while $1.39 was the lowest point it dropped to. The percentage change in LUNG stock occurred in the recent session was -2.07% while the dollar amount for the price change in LUNG stock was - $0.03.

LUNG's industry and sector of operation?

The NASDAQ listed LUNG is part of Medical - Devices industry that operates in the broader Healthcare sector. Pulmonx Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LUNG?

Mr. David A. Lehman
Gen. Counsel & Sec.
Ms. Lisa Paul
Chief People Officer
Mr. Sri Radhakrishnan
Chief Technical Officer
Mr. Geoffrey Beran Rose
Chief Commercial Officer
Ms. Marcee M. Maroney
Vice President of Marketing
Mr. Jérôme Erath
Senior Vice President & GM of Europe Middle-East & Africa
Sarah Huber
Vice President of Sales (U.S.)
Dr. Derrick Sung Ph.D.
Chief Financial Officer
Ms. Lauren Cristina
Vice President of Fin. & Admin. (U.S.)
Mr. Glendon E. French
Chief Executive Officer, Pres & Director

How LUNG did perform over past 52-week?

LUNG's closing price is 8.4% higher than its 52-week low of $1.31 where as its distance from 52-week high of $9.37 is -84.84%.

How many employees does LUNG have?

Number of LUNG employees currently stands at 291.

Link for LUNG official website?

Official Website of LUNG is: https://pulmonx.com

How do I contact LUNG?

LUNG could be contacted at phone 650 364 0400 and can also be accessed through its website. LUNG operates from 700 Chesapeake Drive, Redwood City, CA 94063, United States.

How many shares of LUNG are traded daily?

LUNG stock volume for the day was 285.47K shares. The average number of LUNG shares traded daily for last 3 months was 668.43K.

What is the market cap of LUNG currently?

The market value of LUNG currently stands at $58.57M with its latest stock price at $1.42 and 41.25M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	291
Beta	0.07
Sales or Revenue	$68.68M
5Y Sales Change%	0.872%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

LUNG Company Profile and Key Details

Pulmonx

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways